AMO Pharma Limited has announced it has secured $25 million in private equity financing.

AMO Pharma, with offices in Philadelphia and London, is a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options.

The investment came from Woodford Investment Management’s Woodford Patient Capital Trust.

AMO Pharma indicated the funding would go toward supporting the company’s efforts to advance two clinical‐stage pipeline assets targeting rare muscular and central nervous system disorders as well as expanding the pipeline through acquisition of additional development-stage products.